Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on BI 1026706 Pharmacokinetics
NCT02513446Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BI 1026706 in diabetic macular edema (DME) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Curve of BI 1026706 From 0 to the Last Quantifiable Data Point at 95 hours and Maximum Concentration of BI 1026706 at 95 hours. Started Sep 2015; status: completed.
02
Drugs
BI 1026706
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02513446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02513446.